Clearance of HIV Type 1 Envelope Recombinant Sendai Virus Depends on CD4+ T Cells and Interferon-gamma but Not B Cells, CD8+ T Cells, or Perforin
Overview
Affiliations
T cell-mediated viral clearance is classically attributed to the CD8(+) T cell subset, but CD4(+) T cells can sometimes assume this role. One such instance was illustrated by the immunization of C57BL/6 mice with HIV-1 envelope, followed by challenge with a recombinant Sendai virus (rSeV-env) carrying a gene for secreted HIV-1 envelope protein. Vaccinated mice that lacked both B cells (microMT) and CD8(+) T cells controlled virus, but control was lost when CD4(+) T cells were depleted. To explain this activity, we questioned whether CD4(+) T cells might utilize perforin for killing of MHC class II-positive targets. We also asked if the process might depend on IFN-gamma, which can upregulate MHC expression and enhance T cell recruitment to sites of virus challenge. To address these possibilities, we vaccinated perforin-KO mice with HIV-1 envelope and challenged them with rSeV-env. We found that perforin was not required for (1) CD4(+) T cell homing to the site of virus challenge, (2) expression of Th1 and Th2 cytokines (including IFN-gamma), or (3) virus clearance. To determine if IFN-gamma was required for protection, we repeated experiments in IFN-gamma-KO animals. In this case, significant protection was lost, although the CD4(+) T cells trafficked readily to the site of infection. In fact, local CD4(+) T cell numbers in vaccinated IFN-gamma- KO mice exceeded those in wild type animals. In both cases, cells were alphass TCR(+), NK-1.1(-), and CD44(+), typifying an activated CD4(+) T cell subset. Taken together, our results showed that HIV-1 envelope recombinant virus clearance was dependent on CD4(+) T cells and IFN-gamma, but occurred in the absence of B cells, CD8(+) T cells, or perforin.
Sealy R, Surman S, Hurwitz J Vaccine. 2017; 35(20):2617-2621.
PMID: 28410812 PMC: 5588898. DOI: 10.1016/j.vaccine.2017.03.073.
Sealy R, Webby R, Crumpton J, Hurwitz J Int Immunol. 2012; 25(3):183-95.
PMID: 23143476 PMC: 3579181. DOI: 10.1093/intimm/dxs107.
Jones B, Sealy R, Zhan X, Freiden P, Surman S, Blanchard J Vaccine. 2012; 30(21):3188-95.
PMID: 22425790 PMC: 3386644. DOI: 10.1016/j.vaccine.2012.03.001.
Respiratory syncytial virus vaccine development.
Hurwitz J Expert Rev Vaccines. 2011; 10(10):1415-33.
PMID: 21988307 PMC: 3255794. DOI: 10.1586/erv.11.120.